Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Mechanism of Action in Major Depressive Disorder
NCT06788249Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by University of Pennsylvania. Primary endpoint: Glutamate Chemical Exchange Saturation Transfer imaging metrics at 9 hours. Started Apr 2026; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06788249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788249.